Profound Medical to launch AI-powered BPH module

Profound Medical (PROF) announced the upcoming launch of its TULSA-AI Volume Reduction module for optimizing the treatment of patients with benign prostatic hyperplasia, or enlarged prostate, at the Radiological Society of North America meeting taking place in Chicago, Nov. 30-Dec. 4. BPH is a non-cancerous enlargement of the prostate gland due to an overgrowth of prostate cells. It is a common condition as men age, often impeding the flow of urine and creating significant lower urinary tract symptoms. Current BPH treatment with transurethral resection of the prostate is largely unchanged over the past 100 years. Many alternative treatment methods have been investigated aiming to improve the patient experience and reduce the rates of complications such as bleeding, erectile dysfunction, loss of ejaculation, and the need to stay in the hospital overnight for one, two or more days. The TULSA Procedure, performed using Profound’s TULSA-PRO system, is the only incision-free procedure for prostate cancer, BPH, and patients who have both prostate cancer and BPH. With the TULSA-AI Volume Reduction module, physicians can efficiently and easily stack multiple prostate cases in one day, using the same device hardware, clinical support staff and reimbursement codes. The TULSA Procedure’s clinical flexibility – along with real-world data demonstrating significantly reduced risk of loss of sexual function and incontinence, and CAPTAIN perioperative data demonstrating the TULSA Procedure’s superiority to Robotic Prostatectomy in blood loss, length of stay, post-op pain and recovery time – is fueling strong demand for the incision-free procedure from both patients and healthcare providers. The Company will also present new data on TULSA-PRO for prostate cancer at both RSNA and the Society for Urologic Oncology in Pheonix, Dec. 2-5.